PF 07104091
Alternative Names: PF-07104091Latest Information Update: 23 Jun 2024
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Solid tumours
- Phase I/II Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data form preclinical trial in Breast cancer and Ovarian cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 17 Oct 2022 Pfizer completes a phase-I trial in healthy volunteers in USA (PO) (NCT05431153)
- 10 Jun 2022 Pfizer initiates a phase I safety trial in healthy volunteers in the US (PO) (NCT05431153)